Low-Cost Lithium Compound shows Promise in Early Alzheimer’s Research,But Experts Urge Caution
Cambridge,MA – Preliminary research suggests lithium orotate,a readily available and inexpensive form of lithium,may hold potential in preventing the progression of Alzheimer’s disease. The findings, stemming from studies at the Massachusetts Institute of Technology (MIT), have sparked both excitement and a call for rigorous clinical trials.
The research indicates that lithium orotate helps maintain neuronal connections, facilitates the clearance of cellular debris, and slows the formation of amyloid plaques and neurofibrillary tangles – hallmarks of Alzheimer’s pathology. Notably, the effective dose used in the study was substantially lower than that used to treat bipolar disorder, approximately one-thousandth of the standard therapeutic dosage.
“This is a very exciting study,” stated Dr.Cai Lihui, Director of the Picower Institute of Learning and Memory at MIT, who was not directly involved in the research. “It provides a very important puzzle piece, shifting focus from solely genetic risk factors to potential environmental and metabolic influences in Alzheimer’s development.”
Professor Yankner, the research host, cautioned against self-medication. “I do not recommend that people take lithium at this stage as it has not been verified as a therapy in the human body. We must always be cautious because results observed in mouse models do not always translate to humans.” He emphasized the urgent need for randomized, controlled clinical trials to validate these findings.
The potential affordability of lithium orotate is a key factor driving interest.Researchers hope that rapid and thorough clinical testing can be conducted due to the low cost of the compound. A delay in initiating these trials, some experts fear, could create a negative perception within the Alzheimer’s research community.
Alzheimer’s disease currently affects over 6.7 million Americans, according to the Alzheimer’s Association, and is projected to reach nearly 13 million by 2050. The global cost of dementia,of which Alzheimer’s is the most common form,is estimated at over $1 trillion annually.
☆Health news is not missed, likes are followedFan page。
☆For more critically important medical news, please visitFree health Network。
Free subscriptionFree Sports Electronic News
Popular events and star news are not missed
No need to draw or grab now to watch news using the APP to ensure you win the prize every dayClick me to download the APP
Follow me to see the activity method
